GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Additional Paid-In Capital

Mersana Therapeutics (STU:0M4) Additional Paid-In Capital : €803.83 Mil(As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mersana Therapeutics Additional Paid-In Capital?


Mersana Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€804.88 Mil) to Dec. 2023 (€791.59 Mil) but then increased from Dec. 2023 (€791.59 Mil) to Mar. 2024 (€803.83 Mil).

Mersana Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€506.41 Mil) to Dec. 2022 (€705.06 Mil) and increased from Dec. 2022 (€705.06 Mil) to Dec. 2023 (€791.59 Mil).

Mersana Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Mersana Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Additional Paid-In Capital Chart

Mersana Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 243.60 417.99 506.41 705.06 791.59

Mersana Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 723.97 789.16 804.88 791.59 803.83

Mersana Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Mersana Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (STU:0M4) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (STU:0M4) » Definitions » Additional Paid-In Capital
Comparable Companies
PEPG RPTX VAXX RIGL PRAX ATRA PDSB GRPH ABOS VOR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MRSN:USA 0M4:Germany
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Website
https://www.mersana.com
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (STU:0M4) Headlines

No Headlines